Tricophyton mentagorphytes, genotype VII (TMVII), has been recognized as a fungal infection of concern in the United States since 2024. Transmission has been associated with skin-to-skin contact similar to sexually transmitted infections (STIs) that can also present with a rash. Recognizing TMVII and initiating systemic treatment promptly are key to reducing the transmission of TMVII. The National Network of Prevention Training Centers, in collaboration with the Centers for Disease Control and Prevention and the Minnesota Department of Health, invites you to attend this timely national webinar on TMVII. Learn the basics of recognizing and assessing TMVII, evidence-based recommendations for therapy, and updates on the prevalence and incidence of TMVII in the United States. This webinar will feature expert guidance from leading voices in infectious disease and will include time for questions and answers.
As a result of this activity, the learner will be able to identify at least two key considerations in the recognition, assessment, and management of tricophyton mentagorphytes, genotype VII (TMVII).
Date: 1/29/2026
Time: 9:00-10:15 AM PST, 10:00-11:15 AM MST, 11:00-12:15 PM CST, 12:00-12:15 PM EST
Tricophyton mentagorphytes, genotype VII (TMVII), has been recognized as a fungal infection of concern in the United States since 2024. Transmission has been associated with skin-to-skin contact similar to sexually transmitted infections (STIs) that can also present with a rash. Recognizing TMVII and initiating systemic treatment promptly are key to reducing the transmission of TMVII. The National Network of Prevention Training Centers, in collaboration with the Centers for Disease Control and Prevention and the Minnesota Department of Health, invites you to attend this timely national webinar on TMVII. Learn the basics of recognizing and assessing TMVII, evidence-based recommendations for therapy, and updates on the prevalence and incidence of TMVII in the United States. This webinar will feature expert guidance from leading voices in infectious disease and will include time for questions and answers.
As a result of this activity, the learner will be able to identify at least two key considerations in the recognition, assessment, and management of tricophyton mentagorphytes, genotype VII (TMVII).
Date: 1/29/2026
Time: 9:00-10:15 AM PST, 10:00-11:15 AM MST, 11:00-12:15 PM CST, 12:00-12:15 PM EST
In October 2025, three clade I mpox cases were identified in Southern California who did not report travel history, or contact with one another. This is indicative of community spread of clade I monkeypox virus (MPXV) in California. All prior cases of clade I mpox in California and in the United States have been associated with international travel to areas in which spread of clade I MPXV is ongoing. The California Department of Public Health (CDPH) continues to work closely with local public health departments to conduct enhanced surveillance to detect additional clade I cases. There have also been recent increases in clade II mpox cases reported in California.
Newly released 2024 STI surveillance data indicate the STI epidemic touches nearly every community and while there are signs of progress, the STI burden remains substantial.
CDC has reviewed and graded the evidence on lenacapavir as PrEP from two clinical trials, which demonstrated strong efficacy in preventing HIV infection among both females and males and found no serious safety concerns. On the basis of a high certainty of evidence for its efficacy and safety derived from the agency’s analysis, CDC strongly recommends lenacapavir, administered every six months as a subcutaneous injection, for HIV PrEP in all people weighing at least 35 kg who would benefit.
This resource provides sexually transmitted infection (STI) programs with suggestions and
considerations for planning, implementing, and evaluating STI prevention program activities. It is written
for STI program managers and staff who have the demanding task of implementing, operating, and
managing a prevention program while navigating constantly changing circumstances
A new voluntary recall by King Pharmaceuticals LLC., a subsidiary of Pfizer, of specific referenced lots of Bicillin® L-A (Penicillin G Benzathine Injectable Suspension). Pfizer is initiating this recall due to particulates identified during visual inspection.
Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation’s largest National HIV Testing Day (NHTD) event. Since 2011, KFF’s Greater Than HIV and Walgreens National HIV Community Partnership has provided more than 93,000 free HIV/STD tests through the in-store NHTD program.
Six jurisdictions that participated in SET-NET reported data on women with syphilis during pregnancy and outcomes that occurred during 2018–2021. Frequencies of adverse outcomes were reported by syphilis treatment status during pregnancy as defined by the 2021 Sexually Transmitted Infections Treatment Guidelines (inadequate, adequate, and no treatment).
The National STD Curriculum is a free, up-to-date educational resource for health care professionals and trainees to learn how to diagnose, treat, and prevent sexually transmitted diseases and infections. The recently released 3rd Edition offers 30 free CME/CNE/CE, 12 free pharmacology CE for advanced practice nurses, and Certificates of Completion.
